Comparative Pharmacology
Head-to-head clinical analysis: REVEFENACIN versus SPIRIVA RESPIMAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: REVEFENACIN versus SPIRIVA RESPIMAT.
REVEFENACIN vs SPIRIVA RESPIMAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Revefenacin is a long-acting muscarinic antagonist (LAMA) that inhibits acetylcholine-mediated bronchoconstriction by blocking M3 muscarinic receptors in airway smooth muscle, leading to bronchodilation.
Long-acting muscarinic antagonist (LAMA) that inhibits acetylcholine at M3 receptors in bronchial smooth muscle, leading to bronchodilation.
REVEFENACIN is not a recognized pharmaceutical agent. No standard dosing information available.
2 actuations (2.5 mcg tiotropium/actuation) once daily by oral inhalation.
None Documented
None Documented
Terminal elimination half-life is 12–15 hours in patients with normal renal function (CrCl >90 mL/min). In moderate renal impairment (CrCl 30–59 mL/min), half-life extends to 24 hours. This supports twice-daily dosing in normal patients but may require dose adjustment in renal disease.
Terminal elimination half-life of 27 hours after inhalation (range 13-50 hours), supporting once-daily dosing due to prolonged receptor binding.
Renal excretion accounts for approximately 70% of elimination, primarily as unchanged drug via glomerular filtration and tubular secretion. Fecal excretion accounts for ~20% with biliary elimination contributing to enterohepatic recirculation. The remaining ~10% is metabolized via CYP3A4 to inactive metabolites.
Renal excretion (60-70% unchanged) and biliary/fecal excretion (30-40%) after IV administration; after inhalation, most of the swallowed dose is eliminated fecally.
Category C
Category C
Anticholinergic Bronchodilator
Anticholinergic Bronchodilator